Vascular Genomics Inc.
This article was originally published in Start Up
San Diego-based virtual start-up Vascular Genomics Inc. is leveraging its proteome research--specifically, proteomic maps of the human vascular endothelium--into therapeutic candidates.
You may also be interested in...
Advocates of proteomics argue that without an understanding of protein interactions, drug researchers will be attempting to paint Old Masters with an incomplete set of genomic paint-by-number instructions.
While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.
While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.